UCLA Medical Center of Hematology/Oncology
Los Angeles, CA
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
MDS Centers of Excellence
Accepting patients
CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Learn more- Tyrosine Kinase (TK) Inhibitor
- FLT3
- Phase 1
Accepting patients
APG-2575 Plus Azacitidine
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS
Learn more- Antimetabolites
- BCL-2 Inhibitor
- Phase 1/2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Learn more- Monoclonal Antibody
- CD47
- Closed Label (Masked)
- Placebo
- Randomization
- Phase 2
Accepting patients
SENTI-202
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
Learn more- Natural Killer Cells (Allogeneic)
- CD33
- FLT3
- Phase 1
- Monoclonal Antibody
- Phase 1